[{"id":5444,"regimens":[{"id":10229,"duration":{"id":4123,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":11336,"name":"Mesenchymal Stem Cells","url":"cure-api2.ncats.io/v1/drugs/11336","rxNorm_id":0,"notes":""},"use_drug":[],"created":"2020-05-05T13:05:08.536864Z","updated":"2020-05-06T00:20:19.340261Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":5444}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7157,"answer":"Imaging","answer_other":"","report":5444},{"id":7158,"answer":"PCR","answer_other":"","report":5444}],"how_diagnosis":[{"id":11808,"answer":"PCR","answer_other":"","report":5444},{"id":11910,"answer":"Imaging","answer_other":"","report":5444}],"author_username":"CURE ID Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3261,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5444}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-04-30T01:39:35.502920Z","updated":"2020-05-05T13:05:08.514263Z","title":"Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. case 2","status":"Approved","anonymous":false,"published":true,"pubmed_id":32257537,"doi":"doi: 10.14336/AD.2020.0228","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32257537","pub_year":2020,"published_authors":"Leng Z\r\nZhu R\r\nHou W\r\nFeng Y\r\nYang Y\r\nHan Q\r\nShan G\r\nMeng F\r\nDu D\r\nWang S\r\nFan J\r\nWang W\r\nDeng L\r\nShi H\r\nLi H\r\nHu Z\r\nZhang F\r\nGao J\r\nLiu H\r\nLi X\r\nZhao Y\r\nYin K\r\nHe X\r\nGao Z\r\nWang Y\r\nYang B\r\nJin R\r\nStambler I\r\nLim LW","article_author_email":"Author email could not be found.","journal":"Aging and disease","abstract":"A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11b\r\nmid\r\n regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2\r\n-\r\n and TMPRSS2\r\n-\r\n which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.\r\nCopyright: © 2020 Leng et al.","article_type":"Original","study_type":"Case Report","number_of_patients":7,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"","age":"61-70 years","sex":"Female","ethnicity":null,"country_contracted":"China","country_treated":"China","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"NR","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"","reminder":false,"when_reminder":"2 weeks","additional_info":"Ever on mechanical ventilation (invasive or non-invasive)?: NR\r\nAuthor defined severe?: Severe\r\nJustification for author-indicated response: \"The administration of intravenous injection of MSCs significantly improved the inflammation situation in severe COVID-19 patients. Due to its unique immunosuppression capacity, the serum levels of pro-inflammatory cytokines and chemokines were reduced dramatically which attracted less mononuclear/macrophages to fragile lung, while induced more regulatory dendric cells to the inflammatory tissue niche. Moreover, the increased IL-10 and VEGF promoted the lung’s repair. Ultimately, the patients with severe COVID-19 pneumonia survived the worst condition and recovery.\r\nTherefore, the fact that transplantation of MSCs improved the outcome of COVID-2019 patients may be through regulating inflammatory response and promoting tissue repair and regeneration.\"\r\n\r\nDay in disease course that symptoms were noted to begin improving: 9\r\nDay in disease course that full resolution of symptoms was noted: NR\r\nDay in disease course that patient was discharged if admitted: NR\r\nJustification for timing of resolution: Table 2","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11336]},{"id":5445,"regimens":[{"id":10228,"duration":{"id":4122,"approximate_duration":"14 days","dates_unknown":true},"drug":{"id":11336,"name":"Mesenchymal Stem Cells","url":"cure-api2.ncats.io/v1/drugs/11336","rxNorm_id":0,"notes":""},"use_drug":[{"id":5983,"answer":"To treat a disease other than the one for which the drug is approved","answer_other":"","regimen":10228}],"created":"2020-05-05T12:55:11.820094Z","updated":"2020-05-06T00:20:19.343037Z","dose":null,"frequency":"","route":"","severity":"Inpatient","severity_detail":null,"comments":null,"report":5445}],"site_of_infection":[],"specific_site":[],"how_outcome":[{"id":7155,"answer":"Imaging","answer_other":"","report":5445},{"id":7156,"answer":"PCR","answer_other":"","report":5445}],"how_diagnosis":[{"id":11809,"answer":"PCR","answer_other":"","report":5445},{"id":11909,"answer":"Imaging","answer_other":"","report":5445}],"author_username":"CURE ID Admin","resistant_drugs":[],"combo_drugs":[],"organisms":[{"id":1887,"name":"Severe acute respiratory syndrome coronavirus 2 (sars-cov-2)"}],"disease_name":"COVID-19","author_qualification":"Medical Doctor","author_affiliation":"FDA/NCATS","author_country":"United States","outcome_computed":"Improved","previous_drugs":[],"comments":[],"article_language":"English","why_new_way":[{"id":3262,"answer":"There is no standard/approved therapy for this disease","answer_other":"","report":5445}],"adverse_event_outcome":[],"is_author":false,"cross_linked_diseases":[{"id":396,"name":"Pneumonia"}],"races":[],"created":"2020-04-30T01:39:35.512993Z","updated":"2020-05-05T13:05:34.617317Z","title":"Transplantation of ACE2 Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. case 6","status":"Approved","anonymous":false,"published":true,"pubmed_id":32257537,"doi":"DOI: 10.14336/AD.2020.0228","article_url":"https://www.ncbi.nlm.nih.gov/pubmed/?term=32257537","pub_year":2020,"published_authors":"Leng Z\r\nZhu R\r\nHou W\r\nFeng Y\r\nYang Y\r\nHan Q\r\nShan G\r\nMeng F\r\nDu D\r\nWang S\r\nFan J\r\nWang W\r\nDeng L\r\nShi H\r\nLi H\r\nHu Z\r\nZhang F\r\nGao J\r\nLiu H\r\nLi X\r\nZhao Y\r\nYin K\r\nHe X\r\nGao Z","article_author_email":"Author email could not be found.","journal":"Aging and disease","abstract":"A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs could cure or significantly improve the functional outcomes of seven patients without observed adverse effects. The pulmonary function and symptoms of these seven patients were significantly improved in 2 days after MSC transplantation. Among them, two common and one severe patient were recovered and discharged in 10 days after treatment. After treatment, the peripheral lymphocytes were increased, the C-reactive protein decreased, and the overactivated cytokine-secreting immune cells CXCR3+CD4+ T cells, CXCR3+CD8+ T cells, and CXCR3+ NK cells disappeared in 3-6 days. In addition, a group of CD14+CD11c+CD11b\r\nmid\r\n regulatory DC cell population dramatically increased. Meanwhile, the level of TNF-α was significantly decreased, while IL-10 increased in MSC treatment group compared to the placebo control group. Furthermore, the gene expression profile showed MSCs were ACE2\r\n-\r\n and TMPRSS2\r\n-\r\n which indicated MSCs are free from COVID-19 infection. Thus, the intravenous transplantation of MSCs was safe and effective for treatment in patients with COVID-19 pneumonia, especially for the patients in critically severe condition.\r\nCopyright: © 2020 Leng et al.","article_type":"Original","study_type":"Case Report","number_of_patients":7,"article_patient_number":"","full_text_available":true,"outcome":"Patient improved","surgery":"","age":"41-50 years","sex":"Male","ethnicity":null,"country_contracted":"China","country_treated":"China","began_treatment_year":"2020","hiv":false,"asthma":false,"lung_disease":false,"diabetes_mellitus":false,"hypertension":false,"cardiovascular_disease":false,"chronic_renal_disease":false,"chronic_liver_disease":false,"immunosuppressant_drugs":false,"intellectual_disability":false,"smoker":false,"other_immunodeficiency":false,"other_comorbid":"hypertension","pregnant":false,"unknown":false,"site_of_disease":"Lungs","clinical_syndrome":"Pneumonia","severity":"Inpatient","prev_treatment":"","unusual":"","drug_treatment_features":"","have_adverse_events":false,"adverse_events":"","when_outcome":"While the patient was still on treatment","follow_up_period":null,"relapse":"","reminder":true,"when_reminder":"2 weeks","additional_info":"Ever on mechanical ventilation (invasive or non-invasive)?: NR\r\nAuthor defined severe?: Severe\r\nJustification for author-indicated response: \"The administration of intravenous injection of MSCs significantly improved the inflammation situation in severe COVID-19 patients. Due to its unique immunosuppression capacity, the serum levels of pro-inflammatory cytokines and chemokines were reduced dramatically which attracted less mononuclear/macrophages to fragile lung, while induced more regulatory dendric cells to the inflammatory tissue niche. Moreover, the increased IL-10 and VEGF promoted the lung’s repair. Ultimately, the patients with severe COVID-19 pneumonia survived the worst condition and recovery.\r\nTherefore, the fact that transplantation of MSCs improved the outcome of COVID-2019 patients may be through regulating inflammatory response and promoting tissue repair and regeneration.\"\r\n\r\nDay in disease course that symptoms were noted to begin improving: 12\r\nDay in disease course that full resolution of symptoms was noted: 12\r\nDay in disease course that patient was discharged if admitted: NR\r\nJustification for timing of resolution: Table 2","previously_treated":"","flagged":false,"other_coinfections":"","disease":630,"drugs":[11336]}]